Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 23,021 shares, a drop of 51.0% from the June 30th total of 46,964 shares. Based on an average daily trading volume, of 97,056 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.
Straumann Stock Performance
Straumann stock traded up $0.23 during mid-day trading on Thursday, hitting $12.64. 21,485 shares of the company were exchanged, compared to its average volume of 144,450. Straumann has a 12-month low of $9.44 and a 12-month high of $13.61. The business’s 50 day simple moving average is $12.34 and its two-hundred day simple moving average is $11.68.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a research report on Tuesday, June 30th. Citigroup restated a “sell” rating on shares of Straumann in a research report on Thursday, July 9th. Barclays reaffirmed an “overweight” rating on shares of Straumann in a research note on Thursday, June 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Straumann in a research report on Tuesday, June 30th. Finally, BMO Capital Markets assumed coverage on shares of Straumann in a report on Wednesday, July 8th. They set an “outperform” rating for the company. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Straumann has an average rating of “Hold”.
About Straumann
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Featured Stories
- Five stocks we like better than Straumann
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
